Lu-177 PSMA I&T Therapy for Prostate Cancer; Treatment Response, Treatment Toxicity, and Survival Results

Acar E., Sonmezer B., DEREBEK E., BEKİŞ R., ÖZDOĞAN Ö., Kaya G. C.

JOURNAL OF BASIC AND CLINICAL HEALTH SCIENCES, cilt.3, sa.3, ss.158-164, 2019 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 3 Sayı: 3
  • Basım Tarihi: 2019
  • Doi Numarası: 10.30621/jbachs.2019.708
  • Dergi Adı: JOURNAL OF BASIC AND CLINICAL HEALTH SCIENCES
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.158-164
  • Anahtar Kelimeler: PSMA, prostate cancer, radioligand therapy, mCRPC, theranostic, precision medicine, LU-177-PSMA-617 RADIOLIGAND THERAPY, RADIONUCLIDE THERAPY, SAFETY, CYCLES
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Purpose: This study aims to evaluate the serum PSA response, Ga-68 PSMA PET/CT response, hematological/nephrological toxicity and survival results of patients with castration-resistant metastatic prostate cancer who are receiving Lu-177 PSMA therapy.